Company news

NextCure, Inc. news in 2024

NextCure, Inc.'s news releases, calls and decks from 2024, newest first.

View company

NextCure Announces Acceptance of IND Application for LNCB74

December 9, 2024

NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results

November 6, 2024

NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting

November 4, 2024

NextCure Provides Business Update and Reports Second Quarter 2024 Financial Results

July 31, 2024

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

May 29, 2024

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

May 1, 2024

NextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024

April 23, 2024

NextCure Appoints Dr. Rakesh Dixit to Scientific Advisory Board

April 3, 2024

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

March 20, 2024

NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances

March 4, 2024

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

January 17, 2024

Decks in 2024